It inhibits proliferation and induces apoptosis in resistant cells by targeting the TLR4/PI3K/Akt/mTOR pathway, suggesting its potential as an adjuvant for enhancing 5-fluorouracil efficacy in CRC treatment [106]. The gene discussed is AKT1; the disease is colorectal carcinoma.